Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


Another step forward in blood-based diagnostics for Alzheimer’s disease

Measurement of phosphorylated tau protein in blood plasma allows Alzheimer’s disease to be distinguished from other neurological diseases and may assist in disease detection during the prodromal stage.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: p-tau181 can be used as a prognostic and confirmatory biomarker for AD.


  1. Bateman, R. J. et al. N. Engl. J. Med. 367, 795–804 (2012).

    Article  CAS  Google Scholar 

  2. Janelidze, S. et al. Nat. Med. (2020).

    Article  PubMed  Google Scholar 

  3. Thijssen, E. H. et al. Nat. Med. (2020).

    Article  PubMed  Google Scholar 

  4. Sato, C. et al. Neuron 97, 1284–1298.e7 (2018).

    Article  CAS  Google Scholar 

  5. Barthélemy, N. R., Horie, K., Sato, C. & Bateman, R. J. J. Prev. Alzheimers Dis. 6, S34–S35 (2019).

    Google Scholar 

  6. Barthélemy, N. R., Mallipeddi, N., Moiseyev, P., Sato, C. & Bateman, R. J. Front. Aging Neurosci. 11, 121 (2019).

    Article  Google Scholar 

  7. Nakamura, A. et al. Nature 554, 249–254 (2018).

    Article  CAS  Google Scholar 

  8. Ovod, V. et al. Alzheimers Dement. 13, 841–849 (2017).

    Article  Google Scholar 

  9. Schindler, S. E. et al. Neurology 93, e1647–e1659 (2019).

    CAS  PubMed  Google Scholar 

  10. Preische, O. et al. Nat. Med. 25, 277–283 (2019).

    Article  CAS  Google Scholar 

  11. Mielke, M. M. et al. Alzheimers Dement. 14, 989–997 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Randall J. Bateman.

Ethics declarations

Competing interests

Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (blood plasma assay) licensed by Washington University to C2N Diagnostics, and R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University has submitted the US provisional patent application ‘Plasma Based Methods for Detecting CNS Amyloid Deposition’ (co-inventor, R.J.B.) and the US non-provisional patent application ‘Methods of Diagnosing and Treating Based on Site-Specific Tau Phosphorylation’ (co-inventors, R.J.B. and N.R.B.).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bateman, R.J., Barthélemy, N.R. & Horie, K. Another step forward in blood-based diagnostics for Alzheimer’s disease. Nat Med 26, 314–316 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing